EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Reduced-dose direct oral anticoagulant versus antiplatelet strategies after left atrial appendage occlusion

Laurent Fauchier, Mathieu Nasarre, Bertrand Pierre, Arnaud Bisson, Gregory Y H Lip

EuroIntervention · 2026-09 · 22 (17) · e935-e945

DOI: 10.4244/eij-d-26-00102 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift EuroIntervention, 2026-09. Verfasst von Laurent Fauchier und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Centre Hospitalier Universitaire Trousseau, Faculté de Médecine, INSERM UMR1327 ISCHEMIA, Tours, France and Université Fran…. Hauptthemen laut MEDLINE: Left Atrial Appendage Closure, Platelet Aggregation Inhibitors, Atrial Fibrillation, Anticoagulants. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The optimal antithrombotic therapy after left atrial appendage occlusion (LAAO) in patients with atrial fibrillation (AF) remains uncertain. Reduced-dose direct oral anticoagulation (DOAC) is increasingly used in clinical practice as an alternative to antiplatelet-based strategies, but comparative outcome data are limited. AIMS: We sought to compare the clinical outcomes associated with low-dose DOAC therapy versus dual antiplatelet therapy (DAPT) or single antiplatelet therapy (SAPT) after LAAO. METHODS: Using the TriNetX Global Network, we identified adult patients with AF who underwent percutaneous LAAO between 2010 and 2025. Three parallel propensity score-matched analyses were conducted: reduced-dose DOAC versus DAPT, SAPT versus DAPT, and reduced-dose DOAC versus SAPT. Outcomes included all-cause death, thromboembolic events, device-related thrombosis, bleeding events, and net clinical benefit (NCB). RESULTS: After matching, 1,773 patients were included in each group for the reduced-dose DOAC versus DAPT comparison (mean follow-up 1.4±1.0 years). Reduced-dose DOAC was associated with lower risks of all-cause death (hazard ratio [HR] 0.79, 95% confidence interval [CI]: 0.65-0.96) and major bleeding (HR 0.87, 95% CI: 0.77-0.98), with no significant differences in ischaemic stroke, thromboembolism, or device-related thrombosis. NCB favoured reduced-dose DOAC (HR 0.87, 95% CI: 0.78-0.96). SAPT was also associated with fewer bleeding events and favourable outcomes compared with DAPT. In the reduced-dose DOAC versus SAPT comparison (1,582 matched patients per group), reduced-dose DOAC showed estimates compatible with a slightly higher risk of major bleeding compared with SAPT (HR 1.14, 95% CI: 1.00-1.30; p=0.06), while mortality, thromboembolic outcomes, and NCB did not differ significantly. CONCLUSIONS: In contemporary practice after LAAO, reduced-dose DOAC therapy was associated with more favourable outcomes than DAPT but showed no clear advantage over SAPT, supporting simplified and individualised post-implantation antithrombotic strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Left Atrial Appendage ClosurePlatelet Aggregation InhibitorsAtrial FibrillationAnticoagulantsAtrial AppendageHumansFemaleAgedMaleTreatment OutcomeAdministration, OralThromboembolismHemorrhageStrokeAged, 80 and overMiddle Aged

Substanzen

Platelet Aggregation InhibitorsAnticoagulants

Autor:innen und Institutionen

  • Department of Cardiology, Centre Hospitalier Universitaire Trousseau, Faculté de Médecine, INSERM UMR1327 ISCHEMIA, Tours, France and Université François Rabelais, Tours, France.
  • Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom.
  • Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
  • Department of Cardiology, Lipidology and Internal Medicine, Intensive Coronary Care Unit, Medical University of Białystok, Białystok, Poland.

Zitieren

APA

Fauchier, L., Nasarre, M., Pierre, B., Bisson, A., & Lip, G. Y. H. (2026). Reduced-dose direct oral anticoagulant versus antiplatelet strategies after left atrial appendage occlusion. EuroIntervention, 22(17), e935-e945. https://doi.org/10.4244/eij-d-26-00102

Vancouver

Fauchier L, Nasarre M, Pierre B, Bisson A, Lip GYH. Reduced-dose direct oral anticoagulant versus antiplatelet strategies after left atrial appendage occlusion. EuroIntervention. 2026;22(17):e935-e945. doi:10.4244/eij-d-26-00102

BibTeX
@article{Fauchier2026,
  author = {Fauchier, Laurent and Nasarre, Mathieu and Pierre, Bertrand and Bisson, Arnaud and Lip, Gregory Y H},
  title = {Reduced-dose direct oral anticoagulant versus antiplatelet strategies after left atrial appendage occlusion},
  journal = {EuroIntervention},
  year = {2026},
  volume = {22},
  number = {17},
  pages = {e935--e945},
  doi = {10.4244/eij-d-26-00102}
}
Kostenlos starten →